SCHEMBL13628140

SCHEMBL13628140

O=C1/C(=N\O)c2c(-c3cccc(F)c3)cccc2N1Cc1cc(F)cc2c1OCOC2

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCRTR1 O43613 1/20 0.35
HCRTR2 O43614 1/20 0.35
POLB P06746 3/20 0.34
NPC1 O15118 2/20 0.34
RAB9A P51151 2/20 0.34
NPSR1 Q6W5P4 1/20 0.34
MAPKAPK2 P49137 1/20 0.34
TDP1 Q9NUW8 2/20 0.34
UBE2N P61088 1/20 0.34
TSHR P16473 3/20 0.34
KDM4E B2RXH2 1/20 0.34
MAPK8 P45983 1/20 0.34
GALR3 O60755 1/20 0.33
NR2F2 P24468 1/20 0.33
ALDH1A1 P00352 2/20 0.32
CXCR5 P32302 1/20 0.32
ALDH3A1 P30838 1/20 0.32
CA12 O43570 1/20 0.32
CA1 P00915 1/20 0.32
CA2 P00918 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13628139 0.95 NPC1 (0.37) HCRTR1HCRTR2POLBNPC1RAB9A
SCHEMBL13628142 0.92 HCRTR1 (0.35) HCRTR1HCRTR2POLBNPC1RAB9A
SCHEMBL13628143 0.88 MAPK8 (0.35) HCRTR1HCRTR2POLBNPC1RAB9A
SCHEMBL13627961 0.86 MAPK8 (0.40) HCRTR1HCRTR2POLBNPC1RAB9A
SCHEMBL13628220 0.86 MAPK8 (0.37) HCRTR1HCRTR2POLBNPC1RAB9A
SCHEMBL13628244 0.86 NPC1 (0.38) HCRTR1HCRTR2POLBNPC1RAB9A
SCHEMBL13628138 0.86 HCRTR1 (0.36) HCRTR1HCRTR2POLBNPC1RAB9A
SCHEMBL13628280 0.86 HCRTR1 (0.38) HCRTR1HCRTR2POLBNPC1RAB9A
SCHEMBL13628147 0.84 HCRTR1 (0.34) HCRTR1HCRTR2POLBNPC1RAB9A
SCHEMBL13628153 0.84 HCRTR1 (0.37) HCRTR1HCRTR2POLBNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7612065-B2 Inhibitors of c-JUN N-terminal kinases (JNK) VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-11-03 US disclosed
US-7612065-B2 Inhibitors of c-JUN N-terminal kinases (JNK) VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-11-03 US disclosed
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) SALITURO FRANCESCO G 2008-02-07 US disclosed
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) SALITURO FRANCESCO G 2008-02-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080033022-A1 Inhibitors of c-Jun N-terminal kinases (JNK) MAP3K1, JUN, MAP3K7 HCRTR1 4016/4885HCRTR2 4025/4885POLB 2623/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.